scheda : hanno fatto di tutto

questa andrà molto lontano

2,5 il prox TP

Results for 2005
Revenue Increases 63.3% Leading to a 91.1% Increase in Operating Income
5/16/2005 9:02:14 AM


HONG KONG, May 16, 2005 (BUSINESS WIRE) -- America Oriental Bioengineering Inc., (AOBO), a rapidly growing Chinese company which produces and distributes a broad range of pharmaceutical and nutriceutical products, announced today record first quarter results for the period ended March, 31, 2005. The Company reported revenue of $9.65 million, a 63.4% increase over first quarter 2004 revenue of $5.91 million. American Oriental had operating income of $3.02 million, an increase of 91.1% over operating income for the 2004 first quarter of $1.58 million. American Oriental generated net income of $2.18 million in the current quarter, or $0.05 per diluted share, an increase of 69.2% compared to $1.26 million, or $0.04 per diluted share for the same quarter last year.


The Company ended the quarter with $12.2 million in cash and cash equivalents, the strongest cash position in its history. AOBO's shareholder's equity increased to $35.3 million, its highest level ever.

AOBO's first quarter results demonstrated that the acquisition of Heilongjiang Songhuajiang Pharmaceutical Limited ("HSPL") has contributed significantly to both revenue and earnings. Through this acquisition, AOBO now offers a broader range of medicinal products in China, such as Shuanghuanglian Lyophilized Powder Injection, which has been in the market for over 15 years. The product is an important antiviral medicine and has become one of the most highly regarded herbal products certified by the Government.

"We continue to rapidly grow our product lines and distribution capabilities, both organically and through acquisition," said Tony (Shujun) Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, Inc. "Recently, we entered into a letter of intent to acquire Heilongjiang Qitai Pharmaceutical Limited ("HQPL"), a leading Chinese distributor of pharmaceuticals. The transaction will provide us, for the first time, with the ability to distribute our products throughout China because of HQPL's strong wholesale and retail distribution network, which should serve as a catalyst for future growth. We believe we are ideally positioned to continue to rapidly increase revenue and earnings."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOBO also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.

SOURCE: America Oriental Bioengineering Inc.

CEOcast, Inc. for American Oriental Bioengineering, Inc.
Ed Lewis, 212-732-4300


Copyright Business Wire 2005

American Oriental Bioengineering's Marketing Initiatives Enhance Results of Recently Acquired Heilongjiang Songhuajiang Pharmaceutical Limited; New Subsidiary Generates $2.5 Million in New Purchase Orders

6/27/2005 8:01:18 AM


BEIJING, Jun 27, 2005 (BUSINESS WIRE) -- American Oriental Bioengineering, Inc. (AOBO), a rapidly growing Chinese company which produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that recent marketing initiatives for Heilongjiang Songhuajiang Pharmaceutical Limited (HSPL), its recently acquired subsidiary, have generated $2.5 million in new orders. For more than 50 years, HSPL has played a leading role in the Chinese pharmaceutical industry. Its focus on R&D resulted in proprietary products such as Shuanghuanglian Lyophilized Powder Injection. The product is an antiviral medicine and a most highly regarded herbal products approved by the China FDA for the treatment of SARS.


The Company recently held a series of promotional meetings in eight provinces and municipalities throughout China, including Heilongjiang, Hebei, Henan, Anhui, Xingjaing, Hunan, Guangdong, Guangxi, Beijing, Tianjing. In these meetings, AOBO's technical and sales and marketing staff hosted agencies, distributors and customers to enhance awareness of HSPL's products. Over 4,150 distributors attended.

"Since acquiring HSPL we have taken several significant initiatives to expand its revenue base," said Tony (Shujun) Liu, AOBO's Chief Executive Officer. "As a private company, we have begun several marketing programs to capitalize on the extensive investments that HSPL has made in product development. We have also increased our customer base through expanded distribution channels, as demonstrated by the strong attendance at our recent meetings. We believe that HSPL's unique product line affords AOBO a competitive advantage in the market, and we plan to capitalize on many of its innovative products through further marketing activities in the second half of the year."

C O R R E C T I O N -- Westminster Securities Corporation/
7/21/2005 2:59:56 PM



ATLANTA, July 18, 2005 /PRNewswire via COMTEX/ -- In the news release, Westminster Securities Initiates Equity Research Coverage of American Oriental Bioengineering, Inc. (AOB), issued Monday, July 18, by Westminster Securities Corporation over PR Newswire, we are advised by the company that the third paragraph should read "AOB is an investment banking client of Westminster Securities Corporation, which makes a market in the trading of AOB shares" rather than "which does not make a market in the trading of AOB shares" as originally issued inadvertently. Complete, corrected release follows.

Westminster Securities Initiates Equity Research Coverage of American Oriental
Bioengineering, Inc. (AOB)


Westminster Securities Corporation has today initiated equity research coverage of Harbin, People's Republic of China-based American Oriental Bioengineering, Inc. (AOB) with a "Strong Buy" investment rating, a six-month Target Price of $ 4.05, a 12-month Target Price of $ 4.50, and a risk rating of "High" over both time periods.

American Oriental Bioengineering is a manufacturer and distributor of herbal-based medicines, health supplements and soybean peptide products, all of which the company manufactures in China using organic raw materials. The company has been expanding its operations at a rapid pace over the past two years via selective acquisitions of other Chinese companies with complementary products or product distribution capabilities.

AOB is an investment banking client of Westminster Securities Corporation, which makes a market in the trading of AOB shares.

For further information or a copy of Westminster Securities Corporation's latest equity research report covering AOB please contact:

William D. Lyons, Director of Equity Research
(wlyons@westminstersecurities.com)
Westminster Securities Corporation, 3827 Roswell Road, Suite 100-A,
Atlanta, Georgia 30062; Phone: (770) 321-6799; Fax: (770) 321-2253


Westminster Securities Corporation is a full service New York Stock Exchange member firm operating in six principal areas: Investment Banking, Equity Research, Execution Services, Clearing and Operations and Institutional and Retail Account Management. Combining the responsiveness of a boutique firm with the financial expertise of a long established institution, Westminster provides its services to corporations, institutions, private clients, and investment professionals worldwide. Founded in 1971, Westminster is a member of the New York Stock Exchange, National Association of Securities Dealers (CRD number 6105), and the Securities Investor Protection Corporation. Westminster is headquartered at 100 Wall Street, New York, with branch offices in Atlanta, New York, Miami, St. Louis, Toronto, Limassol (Cyprus) and Shanghai (People's Republic of China).

SOURCE Westminster Securities Corporation

William D. Lyons, Director of Equity Research of Westminster Securities Corporation,
+1-770-321-6799, or fax, +1-770-321-2253, or wlyons@westminstersecurities.com


http://www.prnewswire.com


Copyright © 2005 PR Newswire. All rights reserved.

chiude a 2.31 $

up p.e..ppo.n.s

chiusura sui 2,5....buoni i volumi,,,
l'impressione e che la corsa continui....
meglio cosi.,,, l.ov.e i-lo-ve

ciao paolino, 2.6 adesso

discesa nei gg scorsi, ora nuova battuta d'arresto a 2.5

ha dimostrato una buona tenuta nei giorni scorsi,,,
e possibile che nel breve faccia nuovi max,,, r.i.c.e.. do.la.k..

aggiornamento,,,

per ora tiene 2,5 con discreta disinvoltura,.,,

sperem,,,,

X Paolino

Aggioranamento grafico (by staff)

oggi 2,2
cerco suggerimenti operativi,,,,

grazie

Paolo

+20 % punta a 3 bigliettoni p.e..ppo.n.s

American Oriental Bioengineering Reports Record 2005 Second Quarter Results
MONDAY, AUGUST 15, 2005 8:00 AM



HONG KONG, Aug 15, 2005 (BUSINESS WIRE) -- America Oriental Bioengineering, Inc. (AOB) , a rapidly growing Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today record second quarter and six-month results for the period ended June 30, 2004. The Company generated 2005 second quarter revenue of $11.9 million, a 98.2% increase compared to $6.0 million for the same period in 2004. American Oriental Bioengineering generated Income from Operations of $4.4 million, a 140.9% increase from $1.9 million in the 2004 second quarter. The Company had net income of $3.4 million, or $0.08 per basic and diluted share, a 122.6% increase versus $1.5 million, or $0.05 per basic and diluted share, for the comparable period in 2004.

For the six months ended June 30, 2005, American Oriental Bioengineering Inc. had revenue of $21.6 million, an increase of 81% compared to $11.9 million for the same six-month period in 2004. The Company reported Income from Operations of $7.5 million, a 117.8% increase from the $3.4 million reported for the same period in fiscal 2004. American Oriental Bioengineering generated net income of $5.5 million, or $0.14 per basic share ($0.13 per diluted share), a 100% increase compared to $2.8 million, or $0.08 per basic and diluted share for the first six months of fiscal 2004.

The Company ended the period with its strongest balance sheet ever, as it had cash and cash equivalents at June 30, 2005 of $11.4 million compared to $5.4 million at the end of the first six months of 2004.

Second quarter sales of the Company's PBP Products increased by 223% as compared to the same period in 2004, contributing to American Oriental Bioengineering's strong results. This growth was primarily a result of an increase in sales of Cease Enuresis Soft Gel products. Also, the acquisition of HSPL contributed to the increase in sales of PBP Products due to a broader product line. Sales of PBN Products increased by 21%, as a result of increased marketing and sales initiatives.

"We continue to experience rapid growth as a result of our innovative products and expanded distribution capabilities," said Tony (Shujun) Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, Inc. "The acquisition of HSPL has enabled us to expand our product line and enter new markets. Through the combination of new product initiatives and expanded sales and marketing activities and a strong balance sheet, we believe we are well positioned to continue to generate strong organic growth and to selectively pursue accretive acquisitions."

cerco un po' d'Africa in giardino,
fra l'oleandro e il bAOBab

Le nere su AOB sono a :

$ 3.63

$ 4.09 ( gli aggiungi 4/5 tick al giorno, a questa)


----------------------------------------------------------------------------
----------------------------------------------------------------------------


le ultime sedute viste a modo mio
(Qua trovi il resto ...

ta.m.bu.

e anche de più

peccato perche a 2,2 voleva incrementare ma e mancato l'input sul timing,,,

comunque a 3,1 ho recuperato il capitale,,,(160% gain l.ov.e )
tengo solo quelle gratis,,,che sono diverse,,

Exchange=AMEX
Size=Micro-Cap
Primary SIC Code=3834  (Pharmaceutical Preparat)
CIK=0001090514
NAICS=325412  (Pharmaceutical Preparation Manufacturing)
QM ID=510 (Drug Manufacturers - Major)
Adr=NO
Country-Adr=nn

American Oriental Bioengineering, Inc.. The Group's principal activities are to manufacture and formulate supplemental and medicinal products using proprietary processes. The Group focuses on new product research to combine biotechnology and Chinese medical technology to capture the increasing demand for traditional Chinese medicines and health supplements. The Group owns and operates several plants in addition to a large capacity soybean peptide manufacturing plant. Soybean Peptides are used widely in general food and health food products, sports foods, medicines, the fermentation industry and environmental protection applications. These are easily absorbed by the body and can lower blood pressure and blood fat levels, enhance immunity, lower cholesterol, prevent cardiac and brain blood vessel diseases and inhibit the growth of tumors. On 12-Oct-2004, the Group acquired Heilongjiang Songhuajiang Pharmaceutical Limited. The Group operates throughout the United States.

Industry  Drugs 
Sector  Healthcare 

American Oriental Bioengr Inc (AMEX)  AOB)
Xuefu Road No 308 
Nangang District Harbin 150086
Phone: +86 451 8666-6601
Fax: +86 451 8669-0967

http://www.bioaobo.com/

Investor Relation

Number of Employees 762

Competitors

News/Headlines (YAHOO)


Top Executives
Tony Liu    Chairman/CEO 
Li Yanchun    CFO/COO/Secretary 
Zhang Mowen    Dir. of Marketing 


Index Memberships NN

Book Value: $ 0.88

Revenue-EPS summary

scheda aggiornata

tr.om.b.a

3.6 p.e..ppo.n.s + 14.3 %

3,71

p.e..ppo.n.s

3.74 hai lasciato 3 tick al benzinaio

p.e..ppo.n.s

tutto bene,,per ora
con un po di kulo si va a 4,5..


:D

by staff

chi intravede un entry point?

dura rispondere, aspetterei almeno un po di scarico del demarker

by staff

4,13$ (seconda nera dinamica)

uscito parzialmente a 3,9 e 3,5
ne tengo 1000 per ricordo sperando in qualche eccesso di interesse nei prossimi giorni,,,

da osservare la chiusura di oggi,,,IMO t.ra.de.

ola,,,

by staff

io provo a 3.1

by staff

beh

fin'ora aspettare non t'e' costato molto :D


Sotto...
visto come si sono comportati in passato potrebbero servire
anche sotto $ 3 (intraday) per poi recuperare subito
Prima ci sono due buone statiche rosse a $ 3.37 e a $ 3.12

-----------------------------------------------------------------

-------------------------------------------------------------

08/26/05 20:01:42 3.29 3.28 3.29 1.043.000


Per ora ha servito fino a $ 3.22

-------------------------------------------------------------------------

In concomitanza di questo fine settimana
abbiamo nella prossima ottava

fine e inizio mese...
e l'obiettivo al rialzo
rimane ambizioso (area $ 4.95 )

................................................................................
...........

Ci stupira' ? se.re na.t p.p.p.q

se raggiunge area 3$ io entro sicuro,,,,,,target ambiziosi anche secondo me,,,,,

by staff

AOB ....intraday ( con due tipi di PIVOT) il classico + Woodies

anche se si sbaglia di una decina di tick non è la fine del mondo, AOB è buona anche nel long

Il dubbio e' su
che giornata sara'
lunedi' per AOB

40 tick (per le mie tasche) non sono 10 ...

Non sono neppure certo che inizi bene settembre,
e' solo una mia ipotesi ...

chi troppo vuole

ora 3,71 $

by staff

4,05

Oggi sta un po' piu' in alto...(5 tick)
ma ci siamo quasi

140% dei volumi medi... un treno in corsa

08/31/05 20:09:45 4.08 4.08 4.08 1372100

Nuovi max ta.m.bu.

siamo fresconi , BCON a 3.2 è difficile, mi sa che cambio l'ordine e la pago 10 tick de +, altrimenti finisce come con AOB